Navigation Links
Cyberonics Announces Exclusive Distribution Agreement With Nihon Kohden in Japan
Date:6/1/2009

HOUSTON, June 1 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX) today announced the signing of an exclusive agreement with Nihon Kohden Corporation for the distribution of VNS Therapy Systems for epilepsy patients in Japan. The companies are working together to obtain the necessary regulatory and reimbursement approvals.

"We are very excited to partner with Nihon Kohden to make VNS Therapy available to Japanese patients who suffer from refractory epilepsy," commented Dan Moore, Cyberonics' President and Chief Executive Officer. "Nihon Kohden is a premier manufacturer and distributor of medical devices in Japan with extensive, long-term experience in neurology. Nihon Kohden is our representative to the Japanese Ministry of Health, Labour and Welfare, and this agreement represents an important milestone toward our goal to bring VNS Therapy to one of the largest medical device markets in the world."

"The VNS Therapy System is a perfect addition to our product line for the neurology area," said Fumio Suzuki, President and COO of Nihon Kohden. "Along with our long-term EEG monitoring systems for diagnosis of epilepsy, our goal is to make VNS Therapy Systems a standard of care for refractory epilepsy in Japan."

About Cyberonics, Inc. and VNS Therapy(TM)

Cyberonics, Inc. (Nasdaq: CYBX) is a medical technology company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the treatments of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics, Inc. and VNS Therapy(TM) is available at www.cyberonics.com and www.vnstherapy.com.

About Nihon Kohden

Nihon Kohden is Japan's leading manufacturer, developer and distributor of patient monitors, defibrillators, ECGs, EEGs, EP/EMGs, hematology analyzers and other medical electronic equipment, with subsidiaries in the United States, Europe, and Asia, and distributors in nearly every country in the world. Nihon Kohden is a publicly held company listed in the First Section of the Tokyo Stock Exchange. In addition to designing medical equipment for hospital and clinic use, Nihon Kohden actively contributes to the advance of medical technology.

Safe harbor statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology, including "may," "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," and "forecast," or other similar words. Statements contained in this press release are based upon information presently available to us and assumptions that we believe to be reasonable. We are not assuming any duty to update this information should those facts change or should we no longer believe the assumptions to be reasonable. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning approval for the marketing of VNS Therapy for epilepsy in Japan and making VNS Therapy Systems a standard of care in Japan. Our actual results may differ materially. Important factors that may cause actual results to differ include, but are not limited to: continued market acceptance of VNS Therapy and sales of our product; the development and satisfactory completion of clinical trials and/or market test and/or regulatory approval of VNS Therapy for the treatment of other indications; satisfactory completion of post-market studies required by the U.S. Food and Drug Administration as a condition of approval for the treatment-resistant depression indication; adverse changes in coverage or reimbursement amounts by third-parties; intellectual property protection and potential infringement claims; maintaining compliance with government regulations and obtaining necessary government approvals for new indications; product liability claims and potential litigation; reliance on single suppliers and manufacturers for certain components; the accuracy of management's estimates of future expenses and sales; the results of the previously disclosed governmental inquiries; the potential identification of material weaknesses in our internal controls over financial reporting; risks and costs associated with such governmental inquiries and any litigation relating thereto or to our stock option grants, procedures, and practices (including the previously disclosed private litigation); uncertainties associated with stockholder litigation; and other risks detailed from time to time in our filings with the Securities and Exchange Commission (SEC). For a detailed discussion of these and other cautionary statements, please refer to our most recent filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended April 25, 2008 and our Quarterly Reports of Form 10-Q for the fiscal quarters ended July 25, 2008 and October 24, 2008.

    Contact information

    Greg Browne, CFO
    Cyberonics, Inc.
    100 Cyberonics Blvd.
    Houston, TX 77058
    Main:  (281) 228-7262
    Fax:  (281) 218-9332
    ir@cyberonics.com


'/>"/>
SOURCE Cyberonics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cyberonics Licenses Obesity-Related Patents
2. Cyberonics Announces Conference Call to Discuss FY08 Q3 Financial Results
3. Cyberonics Reports Operating Profit for Third Quarter FY08 and Announces Share Repurchase Program
4. Cyberonics Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2008 Financial Results
5. Cyberonics to Present at Collins Stewart Fourth Annual Growth Conference
6. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 First Quarter Financial Results
7. Cyberonics to Present at Canaccord Adams 28th Annual Global Growth Conference
8. Cyberonics to Present at UBS Global Life Sciences Conference
9. Cyberonics Corporate Headquarters Fully Operational Following Hurricane Ike
10. Cyberonics Provides Business Update Based on Final Ambulatory Payment Classification Rate Change Announcement by CMS
11. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... LINCOLN, R.I. (PRWEB) , ... May 26, 2016 , ... ... season. That’s why Amica Insurance is sharing tips to make sure your ... an estimate from the National Safety Council, there may be 439 deaths and an ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Lung Institute has partnered with ... class starting June 6 at their clinic in downtown Tampa. The class is complimentary ... Lung Institute has created a free downloadable 4 Week Smoking Cessation Guide ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... of Mehling Orthopedics and chief medical officer of Blue Horizon International (BHI), Brian ... Regeneration. The conference was held during May 5-6, 2016 in Chicago, IL, USA. ...
(Date:5/26/2016)... ... May 26, 2016 , ... Power Systems, a leading developer ... Instructor Certification Course in Stoughton, Massachusetts. The course was led by Power Systems’ ... 8 hour interactive course to qualify participants as certified PowerWave trainers. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... On May 23rd during the National ... Science® and international water advocate, was honored by Ashram, Inc. as the world’s foremost ... who knelt on the banks of the Nile to fill their red clay pots ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... FDA 510(k) clearance covers ... for urological and surgical applications Mauna ... Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, ... US with the 12 th 510(k) clearance ... This new FDA clearance covers Confocal Miniprobes indicated ...
(Date:5/25/2016)... , May 25, 2016  Zymo Research ... for their new reference materials that help researchers ... sample collection to analyses. The rapid growth of ... for researchers to have standard methods to improve ... generated. Biases inherently exist at every step of ...
(Date:5/25/2016)... 2016  Granger Diagnostics today announced immediate availability of ... infections. This test ensures discovery of ALL bacteria, ... test requires only a simple swab of the wound ... G. Bostwick , MD, Chief Medical Officer, described ... "We are excited to make available, for the ...
Breaking Medicine Technology: